title: Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy.
abstract: OBJECTIVE
  Medical management of brain tumor-related epilepsy is complicated by interactions between antiepileptic and chemotherapeutic drugs. We studied the effect of temozolomide therapy on the disposition of the new antiepileptic drugs topiramate (TPM) or oxcarbazepine (OXC).
  
  
  METHODS
  Fifteen patients chronically treated with TPM or OXC in monotherapy starting a chemotherapeutic treatment with temozolomide were enrolled in the study, of which ten were available for the final analyses. Blood samples were collected before temozolomide treatment (T(0)), at its end (T(7)) and after further 1-3 weeks (T(14)-T(28)). For each patient, more than one treatment cycle was studied. Topiramate and OXC mono-10-hydroxy derivative (MHD) plasma concentrations were determined by hplc coupled with ion spray mass spectrometer (TPM) or ultraviolet (MHD) detection.
  
  
  RESULTS
  Mean TPM concentrations were 5.4 +/- 2.4 microg/ml at T(0) vs. 5.5 +/- 2.4 microg/ml at T(7) (n = 14), and 5.4 +/- 2.4 microg/ml at T(0) vs. 5.6 +/- 2.8 microg/ml at T(14)-T(28) (n = 14). Mean MHD concentrations were 16.4 +/- 7.6 microg at T(0) vs. 18.5 +/- 9.0 microg/ml at T(7) (n = 5), and 16.8 +/- 7.0 microg/ml at T(0) vs. 18.0 +/- 8.7 microg/ml at T(14)-T(28) (n = 8) (all comparisons not statistically significant; Student's t-test for paired samples).
  
  
  CONCLUSIONS
  Temozolomide treatment did not affect TPM plasma concentrations in chronically treated patients. Data for MHD in OXC-treated patients were similar, but, due to the small sample size, results should be interpreted cautiously.These findings confirm that TPM (and possibly OXC) are a reasonable choice of antiepileptic drug in patients with brain tumor-related epilepsy.
authors.affiliation: Center for tumor-related epilepsy, Department of Neuroscience and Cervical-Facial Pathology, National Institute for Cancer "Regina Elena", Via Elio Chianesi 53, 00144 Rome, Italy. maschio@ifo.it
authors.forename: Marta
authors.initials: M
authors.lastname: Maschio
authors.forename: Fiorenzo
authors.initials: F
authors.lastname: Albani
authors.forename: Bruno
authors.initials: B
authors.lastname: Jandolo
authors.forename: Alessia
authors.initials: A
authors.lastname: Zarabla
authors.forename: Manuela
authors.initials: M
authors.lastname: Contin
authors.forename: Loredana
authors.initials: L
authors.lastname: Dinapoli
authors.forename: Alessandra
authors.initials: A
authors.lastname: Fabi
authors.forename: Andrea
authors.initials: A
authors.lastname: Pace
authors.forename: Agostino
authors.initials: A
authors.lastname: Baruzzi
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000097:blood / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000150:complications* / Q000188:drug therapy*; D002220:Carbamazepine / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D005500:Follow-Up Studies; D005632:Fructose / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078330:Oxcarbazepine; D000077204:Temozolomide; D000077236:Topiramate; D055815:Young Adult
chemical_list: D000927:Anticonvulsants; D018906:Antineoplastic Agents, Alkylating; D000077236:Topiramate; D005632:Fructose; D002220:Carbamazepine; D003606:Dacarbazine; D000078330:Oxcarbazepine; D000077204:Temozolomide